摘要
肝细胞癌(HCC)是全球癌症相关死亡的主要原因之一,也是我国临床最常见恶性肿瘤之一。HCC起病隐匿且进展迅速,大多数患者在诊断时已处于中晚期,预后较差。其中甲胎蛋白阴性HCC占HCC病例总数的30%~40%,传统诊断标志物血清甲胎蛋白在该人群中敏感性不足,容易造成漏诊。本综述探讨了经典生物标志物、新型蛋白质标志物、液体活检标志物及代谢组学标志物对甲胎蛋白阴性HCC早期筛查的潜力,旨在提高甲胎蛋白阴性HCC早期诊断率,减轻肝癌疾病负担。
Hepatocellular carcinoma(HCC)is one of the leading causes of cancer-related mortality worldwide and is also one of the most common malignant tumors in clinical practice in our country.HCC is characterized by insidious onset and rapid progression,and most patients are in the advanced stage at the time of diagnosis,resulting in a poor prognosis.Alpha-fetoprotein(AFP)-negative hepatocellular carcinoma(ANHCC)accounts for approximately 30%—40%of all HCC cases,and the traditional diagnostic biomarker,serum AFP,has insufficient sensitivity in this population,which can easily lead to missed diagnoses.This article reviews the potential of classic biomarkers,novel protein markers,liquid biopsy markers,and metabolomics markers in the early screening for ANHCC,in order to improve the early diagnosis rate of ANHCC and reduce the disease burden of liver cancer.
作者
赵思汝
熊枝繁
ZHAO Siru;XIONG Zhifan(Department of Gastroenterology,Liyuan Hospital,Tongji Medical College,Huazhong University of Science and Technology,Wuhan 430060,China)
出处
《临床肝胆病杂志》
北大核心
2025年第11期2390-2396,共7页
Journal of Clinical Hepatology
基金
华中科技大学同济医学院梨园医院院内科研基金(2023LYYYCXTD0002)。
关键词
甲胎蛋白
癌
肝细胞
液体活组织检查
生物标记
肿瘤
alpha-Fetoproteins
Carcinoma,Hepatocellular
Liquid Biopsy
Biomarkers,Tumor
